Gilead Sciences (GILD) 76.24 $GILD
Intercept Pharmaceuticals: What Investors Need to Watch
Brian Nichols, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
After soaring on positive clinical trial news in January, shares of Intercept Pharmaceuticals have fallen 50% from their highs. The biotech, which currently sports a market cap of $5.5 billion, jumped following positive data from its drug...
Key Takeaways From Gilead Sciences' First Quarter
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Last week, Gilead Sciences revealed first quarter results that took analysts by surprise. Earnings per share of $1.33 came in almost 50% above the average estimate of $0.89. Total revenue of $5 billion was 27.6% above the average estimate of $3.92...
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:29PM CDT
Shares of OncoGenex (OGXI) tumbled 60.3% after it announced that its lead candidate, custirsen, failed to meet its primary endpoint in the phase III, SYNERGY study.
Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:25PM CDT
Affymetrix (AFFX) had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.
Final Glance: Biotechnology companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Hyperion Set to Acquire Andromeda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:58PM CDT
Hyperion entered into a definitive agreement to acquire Andromeda Biotech Ltd. for $12.5 million in cash and 312,869 in Hyperion shares.
Midday Glance: Biotechnology companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
Biotech Tweet of the Week: Will Icahn Attack Gilead?
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 29, 8:30AM CDT
This week, the tweet of the week comes from Paul DeSantis, who questions whether Carl Icahn might get involved with Gilead Sciences considering all the cash the biotech is expected to throw off over the next few years. In the video below, senior...
Athersys (ATHX) in Focus: Stock Slumps 51.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:40AM CDT
Athersys has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SunPower, Tesla, Gilead Among Top Estimate Beaters
at Investor's Business Daily - Mon Apr 28, 8:01PM CDT
It's the middle of earnings season and expectations for investors are high. But it's not just how well you do, but how well you do vs. expectations. Taser International (TASR), Gilead Sciences (GILD), Green Plains Renewable Energy (GPRE), Tesla...
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Global Bronchiectasis Therapeutics Pipeline Review 2014 - Analysis of 15 Companies & 19 Drug Profiles
M2 - Mon Apr 28, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6hzdk/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchiectasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Gilead Sciences, Inc. - Grifols, S.A. - Chiesi Farmaceutici SpA - Zambon Company S.p.A. - Bayer AG - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Edmond Pharma Srl - Savara Inc. - Clarassance, Inc. - Alitair Pharmaceuticals, Inc. - Serendex Pharmaceuticals A/S Drug Profiles - ARD-3150 - ciprofloxacin - aztreonam - ARD-3100 - R&D Progress - AZD-5069 - alpha-1-proteinase inhibitor (human) - BAY-858501 - vancomycin - GSK-2793660 - erdosteine - CG-1011 - Neutrophil Elastases Inhibitors - PUR-0400 - dapsone - ALT-07 - sargramostim - PUR-1000 - ZP-044 For more information visit http://www.researchandmarkets.com/research/q6...chiectasis
Intercept Pharmaceuticals: What Investors Need to Watch
Brian Nichols, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
After soaring on positive clinical trial news in January, shares of Intercept Pharmaceuticals have fallen 50% from their highs. The biotech, which currently sports a market cap of $5.5 billion, jumped following positive data from its drug...
Key Takeaways From Gilead Sciences' First Quarter
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Last week, Gilead Sciences revealed first quarter results that took analysts by surprise. Earnings per share of $1.33 came in almost 50% above the average estimate of $0.89. Total revenue of $5 billion was 27.6% above the average estimate of $3.92...
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:29PM CDT
Shares of OncoGenex (OGXI) tumbled 60.3% after it announced that its lead candidate, custirsen, failed to meet its primary endpoint in the phase III, SYNERGY study.
Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:25PM CDT
Affymetrix (AFFX) had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.
Final Glance: Biotechnology companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Hyperion Set to Acquire Andromeda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:58PM CDT
Hyperion entered into a definitive agreement to acquire Andromeda Biotech Ltd. for $12.5 million in cash and 312,869 in Hyperion shares.
Midday Glance: Biotechnology companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
Biotech Tweet of the Week: Will Icahn Attack Gilead?
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 29, 8:30AM CDT
This week, the tweet of the week comes from Paul DeSantis, who questions whether Carl Icahn might get involved with Gilead Sciences considering all the cash the biotech is expected to throw off over the next few years. In the video below, senior...
Athersys (ATHX) in Focus: Stock Slumps 51.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:40AM CDT
Athersys has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SunPower, Tesla, Gilead Among Top Estimate Beaters
at Investor's Business Daily - Mon Apr 28, 8:01PM CDT
It's the middle of earnings season and expectations for investors are high. But it's not just how well you do, but how well you do vs. expectations. Taser International (TASR), Gilead Sciences (GILD), Green Plains Renewable Energy (GPRE), Tesla...
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Global Bronchiectasis Therapeutics Pipeline Review 2014 - Analysis of 15 Companies & 19 Drug Profiles
M2 - Mon Apr 28, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6hzdk/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchiectasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Gilead Sciences, Inc. - Grifols, S.A. - Chiesi Farmaceutici SpA - Zambon Company S.p.A. - Bayer AG - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Edmond Pharma Srl - Savara Inc. - Clarassance, Inc. - Alitair Pharmaceuticals, Inc. - Serendex Pharmaceuticals A/S Drug Profiles - ARD-3150 - ciprofloxacin - aztreonam - ARD-3100 - R&D Progress - AZD-5069 - alpha-1-proteinase inhibitor (human) - BAY-858501 - vancomycin - GSK-2793660 - erdosteine - CG-1011 - Neutrophil Elastases Inhibitors - PUR-0400 - dapsone - ALT-07 - sargramostim - PUR-1000 - ZP-044 For more information visit http://www.researchandmarkets.com/research/q6...chiectasis
